|
Perceptronix Medical Inc. is a Vancouver-based, privately owned cancer diagnostic company founded in June 1999 as a spin off from the BC Cancer Agency. The Company’s mission is to commercialize effective technologies to improve the early detection, localization, diagnosis and follow-up of cancer with an initial focus on lung cancer. This disease has reached epidemic proportions and typically has a poor outcome (five year survival rate is less than 15%) because symptoms are not usually present until the disease is in an advanced stage.
The Perceptronix suite of services and technologies is aligned with the current cancer diagnostic path used by physicians. Perceptronix services and products offer an improvement over the existing detection and localization technologies, thereby providing physicians with increased options for prolonging patients’ lives and improving their quality of life.
The ClearSign™ sputum test is easily applied to the first step of cancer detection, ClearVu™ and ClearVu™ Elite edoscopy systems (still in development) will assist with accurate localization and ClearCyte™ and ClearPath™ quantitative cytology and pathology workstations contribute to the definitive diagnosis of early lesions and to prognosis.
Each of these services and products is designed to be adopted individually to work with other technologies applied to cancer, or can be adopted together to form an integrated solution for cancer management.
|
|
ClearSign™, ClearCyte™ and Clear2C® (quantitative DNA staining kit) have recently received Canadian and European regulatory approvals while Clear2C® has also received US FDA clearance. Perceptronix currently offers ClearCyte™ tests through its new Quantitative Cytology Laboratory located in Vancouver, BC, Canada and recently opened its first sputum induction facility in Vancouver for Perceptronix’s ClearSign™ sputum test. Completion of ClearVu clinical trials is expected in early 2007 with product launch expected in 2008.
ClearSign™, ClearCyte™ and Clear2C™ are medical devices licensed in accordance with the Food and Drugs Act (Canada) license numbers 72090, 70362 & 70361 respectively, and all three products have the European C Mark - EU Directive 98/79/EC. Clear2C™ has the US FDA Medical Device Listing. For other countries, these devices may be subject to different regulatory requirements. ClearVu™, ClearVu™ Elite, and ClearPath™ devices are in the developmental stage only and have not yet been licensed in accordance with Canadian, or foreign, or international law. Prior to the devices being advertised, sold or distributed for any investigational testing, authorization must be obtained in accordance with the provisions of the Food and Drugs Act (Canada).
Website: www.perceptronix.com
Tel: 604.629.8779 / 888.629.8779
|
| |
|
Product
|
Target Cancer
|
What it does
|
What it is
(Health Canada Risk Classification)
|
Intended benefits
|
Product Pipeline
|
|
ClearSign™
|
Lung
|
Early Detection
|
Cytometry-based sputum cell DNA test
(Class III)
|
Non-invasive test for early lung cancer detection; add-on to standard diagnosis
|
Licensed for sale in Canada & EU
|
|
ClearVu™
|
Lung, oral, bladder, cervix, GI, etc.
|
Early Localization
|
Simultaneous fluoresence and white light endoscopy sytem
(Class II)
|
Finds early cancer lesions; reduces procedure time and physician learning curve
|
In development (R&D), license not yet issued
|
|
ClearVu™ Elite
|
Lung
|
Real-time spectral analysiis endoscopy system
(Class III)
|
Further aids finding early cancer lesions with fewer unnecessary biopsies
|
In development (Clinical), license not yet issued
|
|
ClearPath™
|
Lung, cervix
|
Early Diagnosis & Prognosis
|
Quantitative pathlogy system indexes to reference biopsy image database (workstation)
(Class II)
|
Aids pathology diagnosis of pre-invasive and early invasive cancer
|
In development (Clinical), license not yet issued
|
|
ClearCyte™
|
Lung, oral, bladder, breast, uterine, etc.
|
Early Diagnosis & Prognosis
|
Quantitative high throughput, highly automated cytology system (workstation)
(Class II)
|
Aids early cancer diagnosis & prognosis quickly, easily & in large volumes
|
Licensed for sale in Canada & EU
|
|
Clear2C®
|
Reliable specimen staining
|
Consumable - Quantiative DNA staining kit
(Class I)
|
Quality, convenience, price
|
Licensed for sale in Canada, EU & USA
|
|
Services
|
|
Clinical Laboratory
|
Offers ClearSign™ & ClearCyte™
|
Unique service in Canada for diagnosis and prognosis of lung, bladder, oral, breast, uterine & other cancers
|
|
